Last updated on May 2019

Alvocidib Biomarker-driven Phase 2 AML Study


Brief description of study

The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML patients with demonstrated MCL-1 dependence of 40% by mitochondrial profiling in bone marrow.

Detailed Study Description

In Stage 1 of the study, all eligible AML patients with demonstrated MCL-1 dependence of 40% by mitochondrial profiling in bone marrow will receive treatment with ACM.

In Stage 2, all eligible AML patients with demonstrated MCL-1 dependence of 40% by mitochondrial profiling in bone marrow will be randomized 1:1 to receive either treatment with ACM or CM.

Clinical Study Identifier: NCT02520011

Find a site near you

Start Over

Northside Hospital

Atlanta, GA United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Hudson Valley Cancer Center

Hawthorne, NY United States
  Connect »

University of North Carolina

Chapel Hill, NC United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

University of Iowa

Iowa City, IA United States
  Connect »

Duke

Durham, NC United States
  Connect »

Ochsner Clinic Foundation

New Orleans, LA United States
  Connect »

East Carolina University

Greenville, NC United States
  Connect »

Honor Health Research Institute

Scottsdale, AZ United States
  Connect »

Mayo Clinic Florida

Jacksonville, FL United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Mayo Clinic Rochester

Rochester, MN United States
  Connect »

Morristown Cancer Center

Morristown, NJ United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

West Penn Allegheny Hospital

Pittsburgh, PA United States
  Connect »

Univ Hospital of Bristol

Bristol, United Kingdom
  Connect »